CSTLCastle Biosciences, Inc.

$805M

Q3 2023 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$61M+66.1% YoY

Gross Profit

$50M81.6% margin

Operating Income

-$10M-15.7% margin

Net Income

-$7M-11.2% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

+22.6%

Cash Flow

Operating Cash Flow

$5M

Free Cash Flow

$3M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$436M

Total Liabilities

$50M

Stockholders' Equity

$386M

Cash & Equivalents

$91M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$61M	$37M	+66.1%
Gross Profit	$50M	$28M	+78.2%
Operating Income	-$10M	-$22M	+55.2%
Net Income	-$7M	-$20M	+65.9%

Revenue Segments

Dermatologic

$51M100%

CSTL Q3 2023 Earnings — Castle Biosciences, Inc. Revenue & Financial Results | Market Cap Arena